Sandeep Bhargava, MD
Transplant Hepatology · Haddon Heights, NJNPI 1437109741
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,730 of the $7,596 with a category attached, or 88.6%. 35 manufacturers reported payments, led by AbbVie at 34.8% of the total. 2025 is the largest year on record at $2,364, 2.2 times the $1,061 reported in 2019.
Across 353 payments — averaging $21.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Boston Scientific$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$827
- Johnson & Johnson$518
- Takeda Pharmaceuticals U.S.A., Inc.$477
- Pfizer$347
- plus $2K from 29 others
What the payments were for
- Consulting fees$130%
- Travel & lodging$84111%
- Food & beverage$6,73089%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 124 | $2,640 |
| Boston Scientific | 14 | $1,088 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 53 | $827 |
| Johnson & Johnson | 30 | $518 |
| Takeda Pharmaceuticals U.S.A., Inc. | 27 | $477 |
| Pfizer | 24 | $347 |
| Braintree Laboratories, Inc. | 10 | $248 |
| Lilly USA, LLC | 7 | $231 |
| Gilead | 13 | $197 |
| Abbott | 1 | $140 |
| Phathom Pharmaceuticals, Inc. | 10 | $136 |
| GSK | 1 | $125 |
| Intercept Pharmaceuticals, Inc. | 4 | $55 |
| Regeneron Healthcare Solutions, Inc. | 3 | $51 |
| Ferring Pharmaceuticals Inc. | 3 | $47 |
| Ardelyx, Inc. | 3 | $45 |
| Bristol Myers Squibb | 3 | $44 |
| Novo Nordisk | 2 | $41 |
| Daiichi Sankyo Inc. | 3 | $40 |
| Madrigal Pharmaceuticals | 2 | $35 |
| Ironwood Pharmaceuticals, Inc | 2 | $27 |
| Exact Sciences | 1 | $23 |
| Sanofi | 1 | $20 |
| Corcept Therapeutics | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Covidien LP | 1 | $17 |
| Amgen | 1 | $16 |
| Celltrion USA Inc. | 1 | $16 |
| Kyowa Kirin, Inc. | 1 | $16 |
| Amphastar Pharmaceuticals, Inc. | 1 | $16 |
| Capsovision, Inc. | 1 | $15 |
| Cook Medical LLC | 1 | $15 |
| UCB, Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPYGLASS$492
- Skyrizi$374
- GENERAL - THERAPIES$349
- Rinvoq$224
- FREESTYLE LIBRE 3$140
- SHINGRIX$125
- GENERAL HEMOSTASIS$122
- OMVOH$120
- Humira$114
How this compares
Too few transplant hepatology providers in New Jerseyto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 39 | $25,124 |
| Dexlansoprazole DrDexlansoprazole | 12 | $7,293 |
| Mesalamine | 16 | $4,921 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 76 | $4,879 |
| Pantoprazole Sodium | 325 | $3,595 |
| Omeprazole | 147 | $2,192 |
| Esomeprazole Magnesium | 28 | $2,121 |
| Budesonide EcBudesonide | 13 | $1,684 |
| Lansoprazole | 16 | $1,574 |
| Famotidine | 55 | $734 |
| Lactulose | 14 | $461 |
| Procto-Med HcHydrocortisone | 17 | $278 |
| Metoclopramide Hcl | 11 | $230 |
| Dicyclomine Hcl | 12 | $165 |
| Hydrocortisone | 13 | $92 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $2,640 | $25,12439 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few transplant hepatology providers in New Jerseyon file to place this against a meaningful peer group, so we don't.
Other transplant hepatology in Haddon Heights
- Santiago MunozToms River$877K
- Paul GaglioNewark$304K
- Hisham ElgenaidiCherry Hill$206K
- Ashraf MalekCherry Hill$119K
- Simona RossiCherry Hill$116K
- Daria YuninaSummit$4K
- Nyan LattCamden$2K
- Zaid TafeshNewark$110
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.